Get started

Biotech

$SYBX can rise in the next daysContextual immersion trading strategy idea. Synlogic is a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. The demand for shares of the company looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position from $2,32; stop-loss — $2,15. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:SYBXLong
by KozakHlib
MTNB - Bullish Weekly - Trade the Zones - Play the TicksI actually trade this for 15-20% gains on deep supply zones. Last time I got in was .51 so not bad if you understand where to buy in. I like the swings in this stock and has some volume. Bullish weekly at least to start off next week. Might fail right away with the resistance and the highs. Just need a solid open above .73. Still not banking on that. Just wanted to share a decent penny stock that if you know where to buy in then you can get some decent returns over and over. At least for now. "Reasons Why Long-term Faith on Matinas BioPharma Holdings, Inc. (MTNB) Could Pay Off Investors" investchronicle.com
AMEX:MTNB
by DigitalData
$CDTX can rise in the next daysContextual immersion trading strategy idea. Cidara Therapeutics is a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases The demand for shares of the company looks higher than the supply. Due to the spread of COVID-19, the demand for the company`s services rose. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $2,82; stop-loss — $2,59. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:CDTXLong
by KozakHlib
It's hard to overstate how important the NVAX Phase 3 result isNovavax's Nanoflu isn't your typical new drug-- it's a whole new pharmaceutical technology. So it's hard to overstate how important today's positive Phase 3 clinical trial result is. Positive Phase 3 trial data this morning suggest that Novavax's Virus-Like Particle (VLP)-based flu vaccines will be much more effective than existing egg-based vaccines. When you make a vaccine in an egg, it can mutate in the egg and no longer match the flu strains it's supposed to prevent. The VLP vaccines, by contrast, are genetically identical to the targeted flu strains. This increases the vaccines' effectiveness against the targeted strains. Nanoflu also includes something called "adjuvant Matrix-M," which increases the number of antibodies produced in response to the vaccine by something on the order of 50%. Stronger immune response means greater effectiveness, though it also modestly increased the incidence of adverse events in Novavax's trial. One particular important result from the Phase 3 trial was that Nanoflu was more effective than its competitors against A/H3N2, the most lethal family of flu viruses and the one against which vaccines have traditionally been least effective. I have some friends doing work in this field, and they've told me that there are three really exciting things about these VLP vaccines: 1) they aren't infectious, which makes them safer than using an attenuated virus, 2) they protect against not only the strain of virus they target, but also some mutant forms of it, and 3) they take 12 weeks to produce rather than the traditional 9 months. This last point is the real game-changer. Imagine being able to get vaccines to market in a third of the traditional time. Novavax is also working on a VLP-based Covid-19 vaccine. We can probably expect the FDA to rush approval of both Nanoflu and the CoV-19 vaccine.
NASDAQ:NVAXLong
by ChristopherCarrollSmith
5
$CHMA can rise in the next daysContextual immersion trading strategy idea. Chiasma focuses on developing oral medications using a transient permeability enhancer technology platform for the treatment of rare and serious chronic diseases. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $4,05; stop-loss — $3,96. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
CLong
by KozakHlib
$IMMU can rise in the next daysContextual immersion trading strategy idea. The demand for shares of Immunomedics looks higher than the supply. It is a clinical-stage biopharmaceutical company, which develops monoclonal antibody-based products for the targeted treatment of cancer. On 06APR the company announced that its Phase 3 confirmatory ASCENT study will be halted due to compelling evidence of efficacy. This drug has the potential to be the first FDA-approved conjugate for the treatment of metastatic triple-negative breast cancer — finance.yahoo.com This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $19,37; stop-loss — $18,60. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
ILong
by KozakHlib
$CBPO can fall in the next daysContextual immersion trading strategy idea. The demand for shares of China Biologic Products Holdings looks lower than the supply. This and other conditions can cause a fall in the share price in the next days. So I opened a short position from $99,86; stop-loss — $102,65. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
CShort
by KozakHlib
$MNOV can rise in the next daysContextual immersion trading strategy idea. The demand for shares of MediciNova looks higher than the supply. The company focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs. Due to the spread of COVID-19, the demand for the company`s services rose. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $4,41; stop-loss — $4,21. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:MNOVLong
by KozakHlib
$ATOS can rise in the next daysContextual immersion trading strategy idea. The demand for shares of Atossa Therapeutics looks higher than the supply. The company develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions. Due to the spread of COVID-19, the demand for the company`s services rose. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $1,58; stop-loss — $1,50. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:ATOSLong
by KozakHlib
2
Is $MBRX- The Best Biotech with the most upside Potential Is $MBRX- The Best Biotech with the most upside Potential Just announced a major breakthrough in its effort to develop a new cancer treatment that selectively kills highly resistant tumors. Company has a relatively small OS under 25 Mil and float under 15 Mil . The company is working with the most prestigious cancer centers to treat a broader range of the most difficult cancers like pancreatic cancer. There is a huge unmet medical need in treating these hard to treat cancers and $MBRX break through with STAT3 inhibitors is a game-changer for treating cancer patients. As thing progress I expect this to have 5-10x potential in the relative short term and possible a 50x + in the long term.. One you might want to research and stick away in your IRA .. As i write this stock is 2.05 , recent offer was done ar 2.10 so you know institutional savy investors see major upside and are getting involved at these levels..
NASDAQ:MBRXLong
by InvisbleHand
1
$ASND can rise in the next daysContextual immersion trading strategy idea. The demand for shares of Ascendis Pharma A/S looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $117,86; stip-loss — $114,88 Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:ASNDLong
by KozakHlib